Structural determinants of heparin's growth inhibitory activity. Interdependence of oligosaccharide size and charge.
The glycosaminoglycan heparin inhibits the growth of several cell types in vitro including smooth muscle cells and rat cervical epithelial cells. The commercially available heparin which has antiproliferative activity is a structurally heterogeneous polymer that undergoes extensive modifications during maturation. In this report we have performed structure-function studies on heparin's antiproliferative activity using three different cell types: both rat and calf vascular aortic smooth muscle cells and rat cervical epithelial cells. The minimal oligosaccharide size requirements for antiproliferative activity were determined for the three cell types by using oligosaccharide fragments of defined length prepared by nitrous acid cleavage and gel filtration and a synthetic pentasaccharide. The size requirements are similar but not identical for the different cell types. Hexasaccharide fragments are antiproliferative for all three cell types but the synthetic pentasaccharide inhibits the growth of only the rat and calf vascular aortic smooth muscle cells. The interdependence between size and charge for antiproliferative activity was investigated using chemically modified oligosaccharides as well as oligosaccharides prepared from heparin and separated into fractions of differing charge by ion-exchange chromatography. There is a strong interdependence between size and charge for antiproliferative activity. For example, increasing the charge of inactive tetrasaccharide fragments by O-oversulfation makes them antiproliferative whereas reducing the charge of active larger fragments causes them to loose their antiproliferative activity. Finally the importance of 2-O-sulfate glucuronic acid moieties for antiproliferative activity was investigated using heparin preparations that lack 2-O-sulfate glucuronic acid. These compounds possess antiproliferative activity indicating that 2-O-sulfate glucuronic acid is not required for antiproliferative activity.
Wright
T C
TC
Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115.
Castellot
J J
JJ
Petitou
M
M
Lormeau
J C
JC
Choay
J
J
Karnovsky
M J
MJ
D000818:Animals; D002417:Cattle; D002455:Cell Division / Q000187:drug effects; D002584:Cervix Uteri / Q000166:cytology / Q000187:drug effects; D005260:Female; D006493:Heparin / Q000032:analysis / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects; D009844:Oligosaccharides / Q000032:analysis*; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship
D009844:Oligosaccharides; D006493:Heparin